Moreover, tocilizumab repressed the MCT-1-induced CD44(+)/CD24(−) subpopulations (55.7%) to the control degree (32.5%) (Additional file 5: Figure S5Q), confirming that IL-6R immunotherapy inhibited MCT-1-promoted cancer stemness. The gene discussed is MCTS1; the disease is cancer.